Abstract:BACKGROUND:Recent genomic and bioinformatic technological advances have made it possible to dissect the immune response to personalized neoantigens encoded by tumor-specific mutations. However, timely and efficient identification of neoantigens is still one of the major obstacles to using personalized neoantigen-based cancer immunotherapy.METHODS:Two different pipelines of neoantigens identification were established in this study: (1) Clinical grade targeted sequencing was performed in patients with refractory solid tumor, and mutant peptides with high variant allele frequency and predicted high HLA-binding affinity were de novo synthesized. (2) An inventory-shared neoantigen peptide library of common solid tumors was constructed, and patients' hotspot mutations were matched to the neoantigen peptide library. The candidate neoepitopes were identified by recalling memory T-cell responses in vitro. Subsequently, neoantigen-loaded dendritic cell vaccines and neoantigen-reactive T cells were generated for personalized immunotherapy in six patients.RESULTS:Immunogenic neo-epitopes were recognized by autologous T cells in 3 of 4 patients who utilized the de novo synthesis mode and in 6 of 13 patients who performed shared neoantigen peptide library, respectively. A metastatic thymoma patient achieved a complete and durable response beyond 29 months after treatment. Immune-related partial response was observed in another patient with metastatic pancreatic cancer. The remaining four patients achieved the prolonged stabilization of disease with a median PFS of 8.6 months.CONCLUSIONS:The current study provided feasible pipelines for neoantigen identification. Implementing these strategies to individually tailor neoantigens could facilitate the neoantigen-based translational immunotherapy research.TRIAL REGSITRATION. ChiCTR.org ChiCTR-OIC-16010092, ChiCTR-OIC-17011275, ChiCTR-OIC-17011913; ClinicalTrials.gov NCT03171220.FUNDING:This work was funded by grants from the National Key Research and Development Program of China (Grant No. 2017YFC1308900), the National Major Projects for "Major New Drugs Innovation and Development" (Grant No.2018ZX09301048-003), the National Natural Science Foundation of China (Grant No. 81672367, 81572329, 81572601), and the Key Research and Development Program of Jiangsu Province (No. BE2017607).

Bispecific antibodies targeting mutant RAS neoantigens

Abstract 6717: Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies

Abstract A168: T cell receptor-based bispecific molecules targeting KRAS neoantigen cancer driver mutations

TCR-mimic Antibody-Drug Conjugates Targeting Intracellular Tumor-Specific Mutant Antigen KRAS G12V Mutation

Targeting a neoantigen derived from a common TP53 mutation

Bispecific antibodies catch cancer neoantigens

Identification and affinity enhancement of T-cell receptor targeting a KRAS G12V cancer neoantigen

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Identifying and engineering TCR specificity against solid tumor neoantigens

A Novel Bispecific C-Met/Pd-1 Antibody with Therapeutic Potential in Solid Cancer

Neoantigen Identification Strategies Enable Personalized Immunotherapy in Refractory Solid Tumors

NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors

Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis

A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies

Bi-specific antibody engagers for cancer immunotherapy

Bispecific Nanobody-Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors

Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations